Trial Profile
A phase I trial to investigate HS-120 for the treatment of non-small cell lung cancer (NSCLC)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs HS 120 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 14 Aug 2018 According to a Heat Biologics media release, the company expects to initiate a phase 1 study for ComPACT trial in the fourth quarter of 2018.
- 10 Mar 2016 New trial record
- 07 Mar 2016 The company anticipates filing an IND application by the end of 2016, according to a Heat Biologics media release.